Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy
Cancer homeostasis depends on a balance between activated oncogenic pathways driving tumorigenesis and engagement of stress response programs that counteract the inherent toxicity of such aberrant signaling. Although inhibition of oncogenic signaling pathways has been explored extensively, there is...
Uložené v:
| Vydané v: | Cancer discovery Ročník 14; číslo 7; s. 1276 |
|---|---|
| Hlavní autori: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
United States
01.07.2024
|
| Predmet: | |
| ISSN: | 2159-8290, 2159-8290 |
| On-line prístup: | Zistit podrobnosti o prístupe |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | Cancer homeostasis depends on a balance between activated oncogenic pathways driving tumorigenesis and engagement of stress response programs that counteract the inherent toxicity of such aberrant signaling. Although inhibition of oncogenic signaling pathways has been explored extensively, there is increasing evidence that overactivation of the same pathways can also disrupt cancer homeostasis and cause lethality. We show here that inhibition of protein phosphatase 2A (PP2A) hyperactivates multiple oncogenic pathways and engages stress responses in colon cancer cells. Genetic and compound screens identify combined inhibition of PP2A and WEE1 as synergistic in multiple cancer models by collapsing DNA replication and triggering premature mitosis followed by cell death. This combination also suppressed the growth of patient-derived tumors in vivo. Remarkably, acquired resistance to this drug combination suppressed the ability of colon cancer cells to form tumors in vivo. Our data suggest that paradoxical activation of oncogenic signaling can result in tumor-suppressive resistance. Significance: A therapy consisting of deliberate hyperactivation of oncogenic signaling combined with perturbation of the stress responses that result from this is very effective in animal models of colon cancer. Resistance to this therapy is associated with loss of oncogenic signaling and reduced oncogenic capacity, indicative of tumor-suppressive drug resistance. |
|---|---|
| AbstractList | Cancer homeostasis depends on a balance between activated oncogenic pathways driving tumorigenesis and engagement of stress response programs that counteract the inherent toxicity of such aberrant signaling. Although inhibition of oncogenic signaling pathways has been explored extensively, there is increasing evidence that overactivation of the same pathways can also disrupt cancer homeostasis and cause lethality. We show here that inhibition of protein phosphatase 2A (PP2A) hyperactivates multiple oncogenic pathways and engages stress responses in colon cancer cells. Genetic and compound screens identify combined inhibition of PP2A and WEE1 as synergistic in multiple cancer models by collapsing DNA replication and triggering premature mitosis followed by cell death. This combination also suppressed the growth of patient-derived tumors in vivo. Remarkably, acquired resistance to this drug combination suppressed the ability of colon cancer cells to form tumors in vivo. Our data suggest that paradoxical activation of oncogenic signaling can result in tumor-suppressive resistance. Significance: A therapy consisting of deliberate hyperactivation of oncogenic signaling combined with perturbation of the stress responses that result from this is very effective in animal models of colon cancer. Resistance to this therapy is associated with loss of oncogenic signaling and reduced oncogenic capacity, indicative of tumor-suppressive drug resistance. Cancer homeostasis depends on a balance between activated oncogenic pathways driving tumorigenesis and engagement of stress response programs that counteract the inherent toxicity of such aberrant signaling. Although inhibition of oncogenic signaling pathways has been explored extensively, there is increasing evidence that overactivation of the same pathways can also disrupt cancer homeostasis and cause lethality. We show here that inhibition of protein phosphatase 2A (PP2A) hyperactivates multiple oncogenic pathways and engages stress responses in colon cancer cells. Genetic and compound screens identify combined inhibition of PP2A and WEE1 as synergistic in multiple cancer models by collapsing DNA replication and triggering premature mitosis followed by cell death. This combination also suppressed the growth of patient-derived tumors in vivo. Remarkably, acquired resistance to this drug combination suppressed the ability of colon cancer cells to form tumors in vivo. Our data suggest that paradoxical activation of oncogenic signaling can result in tumor-suppressive resistance. Significance: A therapy consisting of deliberate hyperactivation of oncogenic signaling combined with perturbation of the stress responses that result from this is very effective in animal models of colon cancer. Resistance to this therapy is associated with loss of oncogenic signaling and reduced oncogenic capacity, indicative of tumor-suppressive drug resistance.Cancer homeostasis depends on a balance between activated oncogenic pathways driving tumorigenesis and engagement of stress response programs that counteract the inherent toxicity of such aberrant signaling. Although inhibition of oncogenic signaling pathways has been explored extensively, there is increasing evidence that overactivation of the same pathways can also disrupt cancer homeostasis and cause lethality. We show here that inhibition of protein phosphatase 2A (PP2A) hyperactivates multiple oncogenic pathways and engages stress responses in colon cancer cells. Genetic and compound screens identify combined inhibition of PP2A and WEE1 as synergistic in multiple cancer models by collapsing DNA replication and triggering premature mitosis followed by cell death. This combination also suppressed the growth of patient-derived tumors in vivo. Remarkably, acquired resistance to this drug combination suppressed the ability of colon cancer cells to form tumors in vivo. Our data suggest that paradoxical activation of oncogenic signaling can result in tumor-suppressive resistance. Significance: A therapy consisting of deliberate hyperactivation of oncogenic signaling combined with perturbation of the stress responses that result from this is very effective in animal models of colon cancer. Resistance to this therapy is associated with loss of oncogenic signaling and reduced oncogenic capacity, indicative of tumor-suppressive drug resistance. |
| Author | Fernandes Neto, Joao M Malzer, Elke Morris, Ben Vidal, August Salazar, Ramón Snaebjornsson, Petur van Oudenaarden, Alexander Mainardi, Sara Papagianni, Chrysa Raaijmakers, Jonne A Qin, Wenxin Jansen, Robin A Wailemann, Rosangela A M Te Riele, Hein Medema, Rene H da Silva, Marcelo S Santos, Cristina van Dijk, Emma Yuan, Shengxian Beijersbergen, Roderick L Lieftink, Cor Dias, Matheus Henrique Kuiken, Hendrik J Alvarez-Villanueva, Daniel Wilms, Lieke H S De Conti, Giulia Armelin, Hugo A Dekker, Anna Wang, Siying Kovach, John S Bernards, Rene Friskes, Anoek Jin, Haojie Mourragui, Soufiane Villanueva, Alberto Mulero-Sánchez, Antonio van Gemert, Frank Torres, Thompson E P |
| Author_xml | – sequence: 1 givenname: Matheus Henrique orcidid: 0000-0002-2961-1142 surname: Dias fullname: Dias, Matheus Henrique organization: Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands – sequence: 2 givenname: Anoek orcidid: 0000-0002-9845-3715 surname: Friskes fullname: Friskes, Anoek organization: Division of Cell Biology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands – sequence: 3 givenname: Siying orcidid: 0000-0003-0810-8828 surname: Wang fullname: Wang, Siying organization: State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China – sequence: 4 givenname: Joao M orcidid: 0000-0002-0549-8835 surname: Fernandes Neto fullname: Fernandes Neto, Joao M organization: Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands – sequence: 5 givenname: Frank orcidid: 0009-0000-6076-9469 surname: van Gemert fullname: van Gemert, Frank organization: Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands – sequence: 6 givenname: Soufiane orcidid: 0000-0001-6920-2696 surname: Mourragui fullname: Mourragui, Soufiane organization: Hubrecht Institute-KNAW (Royal Netherlands Academy of Arts and Sciences) and University Medical Center, Utrecht, the Netherlands – sequence: 7 givenname: Chrysa orcidid: 0009-0002-0513-0763 surname: Papagianni fullname: Papagianni, Chrysa organization: Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands – sequence: 8 givenname: Hendrik J orcidid: 0000-0002-1015-4607 surname: Kuiken fullname: Kuiken, Hendrik J organization: Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, the Netherlands – sequence: 9 givenname: Sara orcidid: 0000-0001-7255-6153 surname: Mainardi fullname: Mainardi, Sara organization: Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands – sequence: 10 givenname: Daniel orcidid: 0000-0003-2585-622X surname: Alvarez-Villanueva fullname: Alvarez-Villanueva, Daniel organization: Chemoresistance and Predictive Factors Group, Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Spain – sequence: 11 givenname: Cor orcidid: 0000-0002-2754-4150 surname: Lieftink fullname: Lieftink, Cor organization: Division of Molecular Carcinogenesis, NKI Robotic and Screening Center, The Netherlands Cancer Institute, Amsterdam, the Netherlands – sequence: 12 givenname: Ben orcidid: 0000-0002-9850-6071 surname: Morris fullname: Morris, Ben organization: Division of Molecular Carcinogenesis, NKI Robotic and Screening Center, The Netherlands Cancer Institute, Amsterdam, the Netherlands – sequence: 13 givenname: Anna orcidid: 0000-0002-1000-3788 surname: Dekker fullname: Dekker, Anna organization: Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands – sequence: 14 givenname: Emma orcidid: 0009-0004-1595-2327 surname: van Dijk fullname: van Dijk, Emma organization: Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands – sequence: 15 givenname: Lieke H S orcidid: 0009-0000-1795-6752 surname: Wilms fullname: Wilms, Lieke H S organization: Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands – sequence: 16 givenname: Marcelo S orcidid: 0000-0003-4203-9299 surname: da Silva fullname: da Silva, Marcelo S organization: Department of Chemical and Biological Sciences, Institute of Biosciences, São Paulo State University (UNESP), Botucatu, SP, Brazil – sequence: 17 givenname: Robin A orcidid: 0009-0001-7272-234X surname: Jansen fullname: Jansen, Robin A organization: Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands – sequence: 18 givenname: Antonio orcidid: 0000-0003-1668-7022 surname: Mulero-Sánchez fullname: Mulero-Sánchez, Antonio organization: Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands – sequence: 19 givenname: Elke orcidid: 0000-0002-8529-8234 surname: Malzer fullname: Malzer, Elke organization: Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, the Netherlands – sequence: 20 givenname: August orcidid: 0000-0001-5727-2099 surname: Vidal fullname: Vidal, August organization: Xenopat S.L., Parc Cientific de Barcelona (PCB), Barcelona, Spain – sequence: 21 givenname: Cristina orcidid: 0000-0002-9854-5097 surname: Santos fullname: Santos, Cristina organization: Department of Medical Oncology, Catalan Institute of Oncology (ICO), Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), CIBERONC, Barcelona, Spain – sequence: 22 givenname: Ramón orcidid: 0000-0001-9419-6232 surname: Salazar fullname: Salazar, Ramón organization: Department of Medical Oncology, Catalan Institute of Oncology (ICO), Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), CIBERONC, Barcelona, Spain – sequence: 23 givenname: Rosangela A M orcidid: 0000-0003-4909-9657 surname: Wailemann fullname: Wailemann, Rosangela A M organization: Center of Toxins, Immune-response and Cell Signaling, Instituto Butantan, São Paulo, Brazil – sequence: 24 givenname: Thompson E P orcidid: 0000-0003-1425-9358 surname: Torres fullname: Torres, Thompson E P organization: Department of Clinical and Experimental Oncology, Federal University of São Paulo (UNIFESP), São Paulo, Brazil – sequence: 25 givenname: Giulia orcidid: 0000-0002-2647-228X surname: De Conti fullname: De Conti, Giulia organization: Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands – sequence: 26 givenname: Jonne A orcidid: 0000-0003-1759-8347 surname: Raaijmakers fullname: Raaijmakers, Jonne A organization: Division of Cell Biology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands – sequence: 27 givenname: Petur orcidid: 0000-0002-1086-8108 surname: Snaebjornsson fullname: Snaebjornsson, Petur organization: University of Iceland, Faculty of Medicine, Reykjavik, Iceland – sequence: 28 givenname: Shengxian orcidid: 0000-0002-4883-0156 surname: Yuan fullname: Yuan, Shengxian organization: The Third Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Shanghai, China – sequence: 29 givenname: Wenxin orcidid: 0000-0002-1989-3027 surname: Qin fullname: Qin, Wenxin organization: State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China – sequence: 30 givenname: John S surname: Kovach fullname: Kovach, John S organization: Lixte Biotechnology Holdings, Inc., Pasadena, California – sequence: 31 givenname: Hugo A orcidid: 0000-0001-9557-0804 surname: Armelin fullname: Armelin, Hugo A organization: Center of Toxins, Immune-response and Cell Signaling, Instituto Butantan, São Paulo, Brazil – sequence: 32 givenname: Hein orcidid: 0000-0003-0255-4042 surname: Te Riele fullname: Te Riele, Hein organization: Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands – sequence: 33 givenname: Alexander orcidid: 0000-0002-9442-3551 surname: van Oudenaarden fullname: van Oudenaarden, Alexander organization: Hubrecht Institute-KNAW (Royal Netherlands Academy of Arts and Sciences) and University Medical Center, Utrecht, the Netherlands – sequence: 34 givenname: Haojie orcidid: 0000-0001-9295-1951 surname: Jin fullname: Jin, Haojie organization: State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China – sequence: 35 givenname: Roderick L orcidid: 0000-0003-0116-4130 surname: Beijersbergen fullname: Beijersbergen, Roderick L organization: Division of Molecular Carcinogenesis, NKI Robotic and Screening Center, The Netherlands Cancer Institute, Amsterdam, the Netherlands – sequence: 36 givenname: Alberto orcidid: 0000-0001-5164-0006 surname: Villanueva fullname: Villanueva, Alberto organization: Xenopat S.L., Parc Cientific de Barcelona (PCB), Barcelona, Spain – sequence: 37 givenname: Rene H orcidid: 0000-0002-6754-0381 surname: Medema fullname: Medema, Rene H organization: Division of Cell Biology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands – sequence: 38 givenname: Rene orcidid: 0000-0001-8677-3423 surname: Bernards fullname: Bernards, Rene organization: Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, the Netherlands |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38533987$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkF9LwzAUxYNM3Jz7BiJ59KUz6U3a5nHUvzCYsPlc0vS2RNp0Npm4b2_BKd6Xe87hx4VzL8nE9Q4JueZsybnM7mIuVZTFii3z-yiGiMU8OSOzv3jyT0_Jwvt3No5QQrL0gkwhkwAqS2dk_aoHXfVf1uiWrkywnzrY3tG-phtn-gadNXRrG6db6xqqPdU0187gQHcD6tChC3QbBh2wOV6R81q3HhenPSdvjw-7_Dlab55e8tU6MoKpENUqgbFFyRSgkdoYk2FSgmISq5FAkwITaQxVyVVlyppXWIFMUXEj1OjiObn9ubsf-o8D-lB01htsW-2wP_gCGAMBIhEwojcn9FB2WBX7wXZ6OBa_H4i_AXB_YMc |
| CitedBy_id | crossref_primary_10_1038_s41388_025_03503_z crossref_primary_10_1002_1878_0261_70104 crossref_primary_10_1016_j_biopha_2025_117880 crossref_primary_10_1021_acsaenm_4c00613 crossref_primary_10_1016_j_trecan_2025_04_009 crossref_primary_10_1016_j_tips_2024_04_011 crossref_primary_10_1038_s41587_024_02512_9 crossref_primary_10_3390_pharmaceutics17020189 crossref_primary_10_1016_j_jhepr_2025_101536 crossref_primary_10_1038_s41420_025_02418_8 crossref_primary_10_1039_D4NR05114A crossref_primary_10_1016_j_cbi_2025_111558 crossref_primary_10_1016_j_ccell_2024_04_014 crossref_primary_10_3390_cancers16111989 crossref_primary_10_3390_ijms26062675 crossref_primary_10_1038_s41568_024_00698_3 crossref_primary_10_1038_s44319_024_00128_3 crossref_primary_10_1016_j_celrep_2025_116226 crossref_primary_10_1038_s41389_025_00569_y crossref_primary_10_1186_s42358_024_00427_2 |
| ContentType | Journal Article |
| Copyright | 2024 The Authors; Published by the American Association for Cancer Research. |
| Copyright_xml | – notice: 2024 The Authors; Published by the American Association for Cancer Research. |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1158/2159-8290.CD-23-0216 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2159-8290 |
| ExternalDocumentID | 38533987 |
| Genre | Journal Article |
| GrantInformation_xml | – fundername: European Research Council (ERC) grantid: 787925 – fundername: Instituto de Salud Carlos III (ISCIII) grantid: PI19-01320 and PI22-00548 – fundername: Sao Paolo Research Foundation grantid: 2019/10753-2 – fundername: Shanghai Academic/Technology Research Leader grantid: 22XD1423100 – fundername: São Paulo State Foundation-FAPESP: CeTICS-Grant grantid: 2013/07467-1 – fundername: Instituto de Salud Carlos III grantid: FI20/00130 – fundername: CERCA Program/Generalitat de Catalunya grantid: 2017SGR449 and 2021 SGR 00184 – fundername: National Natural Science Foundation of China (NSFC) grantid: grant 82222047 |
| GroupedDBID | --- 53G 5VS ADBBV AENEX AFHIN AFUMD ALMA_UNASSIGNED_HOLDINGS BR6 BTFSW CGR CUY CVF EBS ECM EIF EJD KQ8 NPM OK1 RCR RHI 7X8 |
| ID | FETCH-LOGICAL-c409t-f963115b093ec5accc8e6b3905edc40ec7304723db19dcbf1ded357e91c49f1d2 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 22 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001260926600015&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 2159-8290 |
| IngestDate | Fri Sep 05 13:03:03 EDT 2025 Mon Jul 21 05:16:09 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | false |
| IsScholarly | true |
| Issue | 7 |
| Language | English |
| License | 2024 The Authors; Published by the American Association for Cancer Research. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c409t-f963115b093ec5accc8e6b3905edc40ec7304723db19dcbf1ded357e91c49f1d2 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0001-9557-0804 0000-0002-9845-3715 0000-0002-9442-3551 0000-0003-1668-7022 0000-0001-8677-3423 0000-0003-0255-4042 0000-0003-1759-8347 0000-0003-1425-9358 0000-0001-5164-0006 0000-0002-1015-4607 0000-0002-2754-4150 0000-0002-6754-0381 0000-0002-2961-1142 0009-0002-0513-0763 0009-0001-7272-234X 0000-0001-7255-6153 0000-0002-0549-8835 0000-0001-9419-6232 0009-0000-6076-9469 0000-0001-5727-2099 0000-0002-8529-8234 0000-0002-9850-6071 0000-0002-1000-3788 0000-0003-4203-9299 0000-0002-9854-5097 0000-0003-4909-9657 0000-0002-1086-8108 0000-0003-0810-8828 0009-0004-1595-2327 0000-0002-2647-228X 0000-0001-9295-1951 0000-0003-0116-4130 0000-0001-6920-2696 0000-0002-4883-0156 0000-0002-1989-3027 0000-0003-2585-622X 0009-0000-1795-6752 |
| OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC11215412 |
| PMID | 38533987 |
| PQID | 3003434643 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_3003434643 pubmed_primary_38533987 |
| PublicationCentury | 2000 |
| PublicationDate | 2024-07-01 |
| PublicationDateYYYYMMDD | 2024-07-01 |
| PublicationDate_xml | – month: 07 year: 2024 text: 2024-07-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Cancer discovery |
| PublicationTitleAlternate | Cancer Discov |
| PublicationYear | 2024 |
| SSID | ssj0000494507 |
| Score | 2.5201213 |
| Snippet | Cancer homeostasis depends on a balance between activated oncogenic pathways driving tumorigenesis and engagement of stress response programs that counteract... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 1276 |
| SubjectTerms | Animals Cell Cycle Proteins - antagonists & inhibitors Cell Cycle Proteins - metabolism Cell Line, Tumor Colonic Neoplasms - drug therapy Colonic Neoplasms - genetics Colonic Neoplasms - metabolism Colonic Neoplasms - pathology DNA Replication Drug Resistance, Neoplasm Humans Mice Nuclear Proteins - genetics Nuclear Proteins - metabolism Protein Phosphatase 2 - metabolism Protein-Tyrosine Kinases - antagonists & inhibitors Protein-Tyrosine Kinases - metabolism Signal Transduction Xenograft Model Antitumor Assays |
| Title | Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/38533987 https://www.proquest.com/docview/3003434643 |
| Volume | 14 |
| WOSCitedRecordID | wos001260926600015&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8NAEF7Uinjx_agvVvC6muxms9mTlGrx0NaCFXoLm91N6SWpTRX9987mUU-C4CWQkIRlMo8v883OIHQTCWlSgPUEPB8lAaeGJNJ4RCacU22EZ5Oyz2xfDIfRZCJHdcKtqMsqG59YOmqTa5cjv2OukwoLIIDez9-Imxrl2NV6hMY6ajGAMs4wxSRa5Vhc7xNe7piGwAbLodKrd8_5PLpbXbvtPhDq2Ew__B1nlvGmt_vfle6hnRpp4k6lGvtozWYHaGtQc-mHqD9SC2XyT_eVcEc3Y85wnuLnTOegWDONX2ZTh9SzKVYFVrjrdGSBx011Oq6b234dodfe47j7ROrZCkTDH92SpGB4IIXEk8xqrrTWkQ0TJj1uDdxhtXB8HGUm8aXRSeobaxgXVvo6kHBGj9FGlmf2FGEOiMIPBCAD6gUq9BMB77BWMBWFqaKqja4bOcWgu46QUJnN34v4R1JtdFIJO55XTTZiBjiCyUic_eHpc7RNAWtUVbQXqJWC5dpLtKk_lrNicVUqBRyHo8E3tkq-7g |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Paradoxical+Activation+of+Oncogenic+Signaling+as+a+Cancer+Treatment+Strategy&rft.jtitle=Cancer+discovery&rft.au=Dias%2C+Matheus+Henrique&rft.au=Friskes%2C+Anoek&rft.au=Wang%2C+Siying&rft.au=Fernandes+Neto%2C+Joao+M&rft.date=2024-07-01&rft.eissn=2159-8290&rft.volume=14&rft.issue=7&rft.spage=1276&rft_id=info:doi/10.1158%2F2159-8290.CD-23-0216&rft_id=info%3Apmid%2F38533987&rft_id=info%3Apmid%2F38533987&rft.externalDocID=38533987 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2159-8290&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2159-8290&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2159-8290&client=summon |